Evaluation of the Discriminative Abilities of Biomarkers for the Diagnosis of Acute Mesenteric Ischemia Compared With Another Similar Clinical Presentation: a Pilot Study

Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Mar 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help doctors diagnose a serious condition called acute mesenteric ischemia (AMI), which happens when blood flow to the intestines is reduced. AMI can be life-threatening if not diagnosed quickly, and currently, the best method for diagnosis is a specialized imaging test called an injected abdominopelvic CT scan. The researchers believe that a substance called adenosine deaminase, which is released when there is injury to the intestines, might be found in higher levels in the blood of people with AMI. By testing blood samples for this substance, the researchers hope to find a quicker and easier way to identify AMI compared to the CT scan.

To participate in this study, you need to be at least 18 years old and experiencing severe abdominal pain that may be caused by AMI. The study will include both men and women, including pregnant or breastfeeding individuals, as they are at higher risk for this condition. Over the course of the study, participants will have their blood tested and will undergo the CT scan to compare results. The trial aims to include 130 people and will last for about two years. If you fit the eligibility criteria and are interested, your involvement could help improve the diagnosis and treatment of AMI in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female, 18 years of age or older
• • with an indication (hyperintense abdominal pain with no obvious diagnosis other than acute mesenteric ischemia) for an injected abdominopelvic scan for hyperintense abdominal pain suspected of acute mesenteric ischemia
• • Including pregnant or breast-feeding women, as this is a risk factor for AMI in young subjects
• • Affiliated with the French social security system
• • Able to express non-opposition in writing
• Exclusion Criteria:
• • Presenting acute myocardial ischemia, to avoid biasing the levels of the biomarkers studied (increased in this clinical situation)
• • Patient in a period of exclusion from another research protocol at the time the non-opposition is signed,
• • Person protected by articles L1121-6 and L1121-8 of the French Public Health Code (deprived of liberty by court order, socially vulnerable, adult incapable or unable to express non-opposition).
• • Persons who are unable to read and understand the French language sufficiently to give their consent to participate in research.